At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 744 enrolled
Drug / intervention
Olumacostat Glasaretil Gel, 5.0% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Vehicle Controlled, Efficacy and Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating Olumacostat Glasaretil Gel, 5.0% and Olumacostat Glasaretil Gel, Vehicle for Acne Vulgaris. Completed, enrolled 744 participants across 46 sites in 3 countries.
Detailed Summary
The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesAustralia, Canada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
First PostedMar 2017
Primary CompletionDec 2017
TodayJul 2026
First PostedMar 8, 2017
Enrollment StartFeb 6, 2017
Primary CompletionDec 21, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.3 years ago
Interventions
Olumacostat Glasaretil Gel, 5.0%drug
Gel containing Olumacostat Glasaretil
Olumacostat Glasaretil Gel, Vehicleother
Vehicle (placebo) gel